BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33441643)

  • 1. Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells.
    Nguyen JP; Bianca M; Huff RD; Tiessen N; Inman MD; Hirota JA
    Sci Rep; 2021 Jan; 11(1):904. PubMed ID: 33441643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.
    Turner MJ; Luo Y; Thomas DY; Hanrahan JW
    Am J Physiol Lung Cell Mol Physiol; 2020 May; 318(5):L908-L920. PubMed ID: 32159371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
    Wong FH; AbuArish A; Matthes E; Turner MJ; Greene LE; Cloutier A; Robert R; Thomas DY; Cosa G; Cantin AM; Hanrahan JW
    Am J Physiol Cell Physiol; 2018 Jan; 314(1):C118-C134. PubMed ID: 28978522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
    Lambert JA; Raju SV; Tang LP; McNicholas CM; Li Y; Courville CA; Farris RF; Coricor GE; Smoot LH; Mazur MM; Dransfield MT; Bolger GB; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Mar; 50(3):549-58. PubMed ID: 24106801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
    Brewington JJ; Backstrom J; Feldman A; Kramer EL; Moncivaiz JD; Ostmann AJ; Zhu X; Lu LJ; Clancy JP
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of long-acting β
    Kim Y; Hou V; Huff RD; Aguiar JA; Revill S; Tiessen N; Cao Q; Miller MS; Inman MD; Ask K; Doxey AC; Hirota JA
    Respir Res; 2021 Oct; 22(1):266. PubMed ID: 34666750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 8A Regulates CFTR Activity in Airway Epithelial Cells.
    Turner MJ; Sato Y; Thomas DY; Abbott-Banner K; Hanrahan JW
    Cell Physiol Biochem; 2021 Dec; 55(6):784-804. PubMed ID: 34936285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.
    De Santi C; Fernández Fernández E; Gaul R; Vencken S; Glasgow A; Oglesby IK; Hurley K; Hawkins F; Mitash N; Mu F; Raoof R; Henshall DC; Cutrona MB; Simpson JC; Harvey BJ; Linnane B; McNally P; Cryan SA; MacLoughlin R; Swiatecka-Urban A; Greene CM
    Mol Ther; 2020 Apr; 28(4):1190-1199. PubMed ID: 32059764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level.
    Cui G; Stauffer BB; Imhoff BR; Rab A; Hong JS; Sorscher EJ; McCarty NA
    Sci Rep; 2019 Sep; 9(1):13460. PubMed ID: 31530897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
    Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
    Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative phase imaging to study transmembrane water fluxes regulated by CFTR and AQP3 in living human airway epithelial CFBE cells and CHO cells.
    Llinares J; Cantereau A; Froux L; Becq F
    PLoS One; 2020; 15(5):e0233439. PubMed ID: 32469934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.